Clinical Trial Update: A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on APG-115 alone or with azacitidine in patients with AML, CMML, or MDS across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• APG-115 (APG-115)
• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: AML, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN